News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

January 24, 2024

Lipidor completes SEK 1.7 million sale of animal segment patent

STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's patents, previously out-licensed to Emollivet AB, has now been sold to the same party. The sale is aimed at strengthening Lipidor's short term cash position. Since its inception…

November 27, 2020

Lipidor presents Nomination Committee

Stockholm, 27 November 2020 – Lipidor’s Annual General Meeting on 11[th] June 2020, adopted an instruction regarding the appointment of the Nomination…

November 19, 2020

Lipidor publishes interim report for Q3 2020

STOCKHOLM, 19 August 2020: Today, Lipidor AB publishes its interim report for the period July – September 2020. The quarterly report is…

October 1, 2020

Lipidor strengthens management through strategic hire

Stockholm, 1 October 2020: Lipidor AB (Nasdaq First North: LIPI) today announces that the company is strengthening its management team through the…

September 30, 2020

Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company’s AKVANO® technology

Stockholm, 30 September 2020 – Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development…

August 18, 2020

Correction: Lipidor publishes interim report for H1 2020

In the last press release, Lipidor published that the information and interim report was such that Lipidor is required to publish under…

August 18, 2020

Lipidor publishes interim report for H1 2020

Today, Lipidor AB publishes its interim report for the period January – June 2020. The quarterly report is available on the company's…

August 11, 2020

Resolutions from Lipidor’s Extraordinary General Meeting

Today, 11 August 2020, Lipidor AB (publ) (the “Company” or “Lipidor”) held an extraordinary general meeting (“EGM”) in Solna, Sweden. The EGM…

July 7, 2020

Lipidor signs agreement with CRO for implementation of Phase III clinical study of drug candidate AKP-02 against Psoriasis

Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity,…

July 7, 2020

Lipidor AB (publ) announces subsidiary Emollivet AB’s recruitment of Stina Linge as CEO

Lipidor AB ("Lipidor") today announces that the subsidiary Emollivet AB ("Emollivet") has recruited Stina Linge as CEO. Stina Linge joins Emollivet from…

June 30, 2020

NOTICE OF EXTRAORDINARY GENERAL MEETING OF LIPIDOR AB (publ)

The shareholders of Lipidor AB (publ) (the "Company") are hereby invited to attend an Extraordinary General Meeting on August 11, 2020 at…